Subscribe Become an Author Sign Up Log In


United Kingdom based
$43.7 M
Research papers


At the forefront of small molecule drug discovery

We are the first company to automate drug design, surpassing conventional human endeavour.

Our AI driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters.

With better information to hand than any researcher could acquire individually, our knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay.

With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals.

Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Business model
  • Operations Service
Therapeutic focus
  • Metabolics
  • Neuroscience
  • Oncology
Data type used for modelling
  • Chemical notations and molecular fingerprints
  • HTS and HCS data
Product type
  • Small molecules
Research focus
  • Drug Repurposing
  • Lead Discovery
  • Preclinical Development

Investing history

2019Series B26.0
2016Series A17.7

Industry Partnerships

2013Janssen Pharmaceuticals
2014Sunovion Pharmaceuticalsdrug discovery and optimization of new drugs for mental illnesses (by analyzing data obtained with phenotype drug discovery)
2015Sumitomo DainipponDeveloped a (lead candidate) bispecific, dual-agonist compound that selectively activates two GPCR families
2016Evotecdiscover and develop first-in-class bispecific small molecule immuno-oncology therapies. The initial focus is cancer-related adenosine targets
2017Sanofidiscover bispecific small-molecule drugs against metabolic diseases. (from excientia: comp. design, target identification)
2017GlaxoSmithKlineuse artificial intelligence to discover new small molecule therapies for up to 10 disease-related targets.
2019RocheExscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for Roche.
2019CelgeneExscientia will leverage its AI drug discovery platform Centaur Chemist for the entire discovery process of small molecule drug candidates in three of Celgene’s therapeutic programme areas within oncology and autoimmunity.

Posts Mentioning This Company

Biopharma Insights
White Papers And Industry Reports
Drug Discovery Insights